Urinary Bladder Neoplasms: all 1,649 studies

Page 8 of 17. Open to participants first (427), then studies with results posted, then the rest; newest registration first within each.

• Intraoperative vs. Postoperative Intravesical Epirubicin Instillation for Prevention of Bladder Recurrence in High-Risk Upper Urinary Tract Urothelial CarcinomaCompletedNCT06941038
• The Impact of Manual Versus Mechanical Intestinal Suturing on the Incidence of Postoperative Complications Following Cystectomy With Ileal ConduitCompletedNCT06928220Not applicable
• Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive CasesActive, not recruitingNCT06870253
• Retrospective Analysis of Different Quadratus Lumborum Block Techniques on Recovery Quality and Analgesic Consumption in Radical Cystectomy PatientsCompletedNCT06851520
• OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIAActive, not recruitingNCT06820502Not applicable
• Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder CancerCompletedNCT06818799Not applicable
• A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)WithdrawnNCT06816017Phase 1
• A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRICompletedNCT06807008
• Loop Resection or Cold-cup Biopsy? a Study Comparing the Accuracy of Muscle Samples During Bladder Tumor SurgeryCompletedNCT06796413Not applicable
• Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab DeviceCompletedNCT06789224Not applicable
• Hyperthermic Intra-Vesical ChemotherapyCompletedNCT06768346Not applicable
• Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT06767982Phase 4
• BCG for Therapeutic Use Phase Ⅲ Clinical TrialActive, not recruitingNCT06747455Phase 3
• The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal ConduitCompletedNCT06688643Not applicable
• Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer PatientsCompletedNCT06657755
• Effect of Tumor Base Size in Bladder CancerCompletedNCT06632340Not applicable
• Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsActive, not recruitingNCT06617169Phase 1
• Enhanced Assistance During Radiotherapy for Unmet Essential NeedsCompletedNCT06582849Not applicable
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
• Study on the Staging and Prognosis Model of Bladder CancerActive, not recruitingNCT06565923
• Urine DNA Methylation Detection for Hematuria EvaluationStatus unknownNCT06427993
• An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their CaregiversActive, not recruitingNCT06414317Not applicable
• Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or CystectomyActive, not recruitingNCT06408597Not applicable
• The Use of Remote Monitoring to Improve Patient-Reported Outcomes and Readmission Rates Following Radical CystectomyCompletedNCT06397040Not applicable
• Trimodality Treatment in Bladder CancerCompletedNCT06395701
• A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.WithdrawnNCT06390111Phase 4
• The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder CancerCompletedNCT06381895
• The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical CystectomyCompletedNCT06358599
• Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)CompletedNCT06350838Phase 1
• Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship StudyActive, not recruitingNCT06350734
• Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour LocationCompletedNCT06337591
• Resiliency in Patients Undergoing Radical Cystectomy for Bladder CancerCompletedNCT06337305
• Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsActive, not recruitingNCT06337084Phase 1
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsTerminatedNCT06336148Phase 1
• Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy PatientsCompletedNCT06307704Not applicable
• A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Active, not recruitingNCT06305767Phase 1/2
• A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised TrialWithdrawnNCT06301308Phase 3
• Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before CystectomyActive, not recruitingNCT06294054
• Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic TherapyWithdrawnNCT06290687Phase 2
• Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in BladderActive, not recruitingNCT06289283
• GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy UnitCompletedNCT06281691
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1
• Comparison of Apixaban Versus EnoxaparinCompletedNCT06243510Not applicable
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabActive, not recruitingNCT06237920Phase 2
• Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder CancerCompletedNCT06235853
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)Active, not recruitingNCT06225596Phase 2
• Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder CancerCompletedNCT06205277
• Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer SurvivorsCompletedNCT06171945Not applicable
• Mobile Ostomates Resources for Patients and CaregiversCompletedNCT06157814Not applicable
• Patterns of Urinary Bladder Cancer in Darfur, SudaCompletedNCT06156787
• Clinical Investigation of the Multi4 SystemCompletedNCT06136312Not applicable
• A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue TestingActive, not recruitingNCT06129084
• Bipolar Enbloc Versus Thulium-Yag Enbloc Resection of Bladder TumorsActive, not recruitingNCT06119724Not applicable
• A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTActive, not recruitingNCT06111235Phase 3
• BCG for Therapeutic Use Phase I Clinical TrialCompletedNCT06100653Phase 1
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossWithdrawnNCT06090318Phase 1/2
• Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological CancersCompletedNCT06087016
• Evaluation of VISIOCYT Bladder Cytology in Real LifeCompletedNCT06072027
• Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.TerminatedNCT06069453Not applicable
• Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder CancerCompletedNCT06059547Phase 2
• A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)WithdrawnNCT06050954Phase 2
• ADSTILADRIN Early Utilization and Outcomes in the Real World SettingTerminatedNCT06026332
• Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder CancerCompletedNCT06020807
• Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to BenchsideCompletedNCT06020651Not applicable
• A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer PatientsCompletedNCT06002269Not applicable
• Physical Therapy in Pre-cystectomy PatientsCompletedNCT05978570
• Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and ChemoradiationActive, not recruitingNCT05975307Phase 2
• Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder CancerCompletedNCT05946369
• Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERCompletedNCT05945108
• Lymph Node Dissection Before or After CystectomyCompletedNCT05939856Not applicable
• Professional Bladder Cancers and the Profession of PainterCompletedNCT05937555
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
• Enhanced Recovery After Surgery (ERAS) for Ambulatory TURBTCompletedNCT05905276Not applicable
• HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyCompletedNCT05902494
• A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of InterestCompletedNCT05899361Not applicable
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
• Current Intensity for the Obturator Nerve BlockCompletedNCT05872451Not applicable
• Integrated Actionable Aging Assessment for Cancer Patients PilotActive, not recruitingNCT05871008Not applicable
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
• Clinical Performance Evaluation of the C2i TestWithdrawnNCT05860543
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• InveStigAting Bladder fiELd-cycLing imAgingWithdrawnNCT05846165Not applicable
• IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05843448Phase 1
• Targeting Androgen Signaling in Urothelial Cell Carcinoma - NeoadjuvantTerminatedNCT05839119Phase 1
• Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder CancerActive, not recruitingNCT05822934Phase 3
• Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical CystectomyCompletedNCT05822518Not applicable
• Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision TherapeuticsTerminatedNCT05819827
• Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor ResectionStatus unknownNCT05787938
• Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBtActive, not recruitingNCT05776758Phase 3
• Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBCActive, not recruitingNCT05768347Phase 1
• Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity DetectionStatus unknownNCT05767528
• A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the BladderCompletedNCT05742867
• Comprehensive Optimization At-time of Radical Cystectomy InterventionWithdrawnNCT05714826Not applicable
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Active, not recruitingNCT05714202Phase 3
• Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingNCT05704244Phase 3
• The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder CancerStatus unknownNCT05704231Not applicable
• A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder CancerTerminatedNCT05699135
• Aschistosoma Haematobiumspecific microRNAas a Tumor Marker for Early Diagnosis and Prognosis of Bilharzial Bladder Cancer in EygptStatus unknownNCT05697224Not applicable
• Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder CancerWithdrawnNCT05687721Phase 1/2

← Urinary Bladder Neoplasms overview